New module designed to provide simple storage of participant consent.
Mednet announced in a company press release its newest software release. Featuring electronic consent capabilities (eConsent) within the iMednet eClinical platform, the organization stated that the new module was designed to provide a simple, cost-effective, and compliant method to collect and store participant consent.
"As the use of electronic consent in clinical trials becomes increasingly necessary across all study types – we are thrilled to add this to our comprehensive toolset," said Rob Robertson, CEO, Mednet, in a company press release. "I am particularly proud of how our team diligently listened to our customers and translated their needs to deliver the optimal combination of functionality, flexibility, and affordability."
Reference: Mednet Launches eConsent Functionality in Latest Release. PR Newswire. October 4, 2023. Accessed October 6, 2023. https://www.prnewswire.com/news-releases/mednet-launches-econsent-functionality-in-latest-release-301947495.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.